Securities & Capital Markets

/Overview

Nixon Peabody’s Securities & Capital Markets Team advises clients across industries and geographies on the full spectrum of securities and corporate finance laws. 

We guide public and private companies, underwriters, and investors through public offerings, private placements, and complex equity and debt financings. Our attorneys bring deep experience in disclosure, compliance, and corporate governance, regularly advising on SEC reporting, proxy matters, stock exchange requirements, and tender offers. 

With a collaborative, business-focused approach, we’ve served as lead counsel on more than 180 offerings, raising billions for our clients. We work across sectors including life sciences, media, real estate, and financial services, delivering strategic, forward-thinking counsel tailored to each client’s goals and growth opportunities.

/Representative experience

• Four Leaf Acquisition Corporation: Represented a SPAC that will seek to combine with one or more companies in the Internet-of-Things (IoT) and related industries, in its pricing of its initial public offering of 5,200,000 units at $10.00 per unit
• Tegna Inc.: Represented an American publicly traded broadcast, digital media, and marketing services company in its private placement offering of $1 billion aggregate principal amount of its 4.625% Senior Notes due 2029 under Rules 144A and Regulation S
• Sumitomo Corporation of Americas: Represented a subsidiary of Sumitomo Corporation, a global trading and investment company, in its strategic equity investment in Vast Medical Holdings
• Sylebra Capital Limited: Represented a global investment firm, in its role as lead investor in revolutionary plastic conversion company, PureCycle Technologies’ private placement offering of Green Convertible Senior Notes due 2030 under Securities Act Rule 144A
• Bally’s Corporation: Represented a global casino-entertainment and interactive gaming company in its acquisition by Standard General L.P. in a take private transaction valued at $4.6 billion 
• Merck KGaA: Represented a leading science and technology company in connection with GSK plc’s $1.15 billion acquisition of IDRx, Inc.; Merck KGaA was a shareholder in IDRx

/Recognition

• Nixon Peabody has been named a Tier 1 National firm for Corporate Law; Securities / Capital Markets Law; and Securities Regulation in the 2024 edition of Best Law Firms®.
• Named one of the 32 most trusted firms for M&A according to the “2022 Dauntless Dealmakers” report by BTI Consulting Group
• Awarded Deal of the Year for multiple transactions in recent years by various sources, including The Deal, the Association for Corporate Growth, and the M&A Advisor
• Recognized as a leader in middle-market mergers, acquisitions, and buyouts by Legal 500 in 2025
• Named as a leading firm in Corporate/M&A by Chambers in 2025
• Over half of our corporate partners and counsel were recognized by Chambers, Legal 500, and The Best Lawyers in America© 2022–2023 as leading attorneys in the field